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Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs, 
including the central nervous system. Neuropsychiatric SLE (NPSLE) is a severe and potentially 
fatal condition. Several factors including autoantibodies have been implicated in the pathogenesis 
of NPSLE. However, definitive biomarkers of NPSLE are yet to be identified owing to the com-
plexity of this disease. This is a major barrier to accurate and timely diagnosis of NPSLE. Studies 
have identified several autoantibodies associated with NPSLE ; some of these autoantibodies are 
well investigated and regarded as symptom-specific. In this review, we discuss recent advances in 
our understanding of the manifestations and pathogenesis of NPSLE. In addition, we describe rep-
resentative symptom-specific autoantibodies that are considered to be closely associated with the 
pathogenesis of NPSLE.
Key words : autoantibody, biomarker, neuropsychiatric systemic lupus erythematosus, pathogene-
sis, symptom-specific
1. Introduction 
Systemic lupus erythematosus (SLE) is a 
chronic autoimmune disease that affects multiple or-
gans, including the central nervous system (CNS)1). 
SLE is characterized by the loss of immune toler-
ance to nuclear antigens due to development of au-
toantibodies and immune complex formation ; the 
resultant complement activation results in cell de-
struction and tissue injury1,2). Patients with SLE 
show considerable variability with respect to symp-
toms. In particular, neuropsychiatric (NP) SLE is a 
severe and potentially fatal condition that is charac-
terized by CNS manifestations1,2). In 1999, the 
American College of Rheumatology Research Com-
mittee developed standard nomenclature and case 
definitions for 19 manifestations of NPSLE (Table 
1)3). NP manifestations usually occur in the early 
stage of SLE and 39%-50% of patients exhibit SLE 
symptoms. The reported prevalence of NPSLE 
varies widely from 4%-91% ; this may be attribut-
able to variability in clinical presentations, different 
selection criteria, and heterogeneity among study 
populations4-6). In a recent 3-year prospective 
study of 370 SLE patients with no history of CNS in-
volvement (excluding non-specific minor CNS com-
plaints and peripheral nervous system symptoms), 
the prevalence of major CNS events was 4.3% with 
an estimated incidence of 7.8 events/100 person-
years7). In spite of recent advances, the diagnosis 
of NPSLE is typically challenging, due in part to the 
absence of specific and reliable laboratory or imaging 
biomarkers2,8). The diagnosis of NPSLE requires 
exclusion of other causes such as infection, concur-
rent disease, metabolic abnormalities, or drug ad-
verse events1,2,5,6,8). Therefore, investigation of dis-
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ease-specific or symptom-specific autoantibodies 
observed in NPSLE is a key imperative to facilitate 
timely and accurate diagnosis. Here, we review re-
cent NPSLE studies that focused on the pathogene-
sis of NPSLE and the autoantibodies associated with 
NPSLE manifestations, especially symptom-specific 
autoantibodies.
2. Pathogenesis of NPSLE 
The pathogenesis of NPSLE is highly complex, 
with detailed mechanisms yet to be elucidated1,2,6). 
The pathogenic pathways suggested thus far include 
blood-brain barrier (BBB) dysfunction, vascular oc-
clusion, neuroendocrine-immune imbalance, and tis-
sue and neuronal damage caused by autoantibodies 
and proinflammatory cytokines [interleukin (IL)-1, 
IL-6, IL-8, IL-10, IL-17, type 1 interferons, tumor 
necrosis factor, colony-stimulating and macrophage-
stimulating factors]1,2,6,8,9). Predisposing genetic 
factors, neuroendocrine factors, and environmental 
factors are also thought to be important. Figure 1 
illustrates the currently proposed pathogenetic 
mechanisms of NPSLE1,2,6).
2.1 Predisposing factors
Predisposing genetic factors are believed to 
play an important role in SLE pathogenesis2,6). In 
NPSLE patients, mutations in TREX1, which en-
codes three-prime repair exonuclease 1 (DNAse 
III), were shown to be associated with neurological 
involvement. Polymorphisms in TREX1 were 
found to be associated with neurological involve-
ment in European patients with SLE10). Loss-of 
function mutations in TREX1 augment the produc-
tion of type 1 interferons in mice and lead to early-
onset cerebral NPSLE11,12). In addition, HLA-
DRB1*04 and rs10181656(G) alleles were shown to 
be associated with ischemic cardiovascular disease 
(CVD) in Caucasian patients with SLE13,14). More 
recently, Rullo et al. reviewed recent advances in our 
understanding of the genetic basis of SLE, including 
genetic variants in recently identified SLE-associat-
ed loci, the immunological pathways affected by 
these gene products, and the disease manifestations 
linked to these loci15). In addition, environmental 
factors and neuroendocrine factors play an important 
role in the development of SLE. In previous stud-
ies, silica exposure, smoking, oral contraceptives, 
postmenopausal hormone therapy, and endometrio-
sis were found to be risk factors for SLE16).    Indeed, 
sex steroid hormones (17β-estradiol, testosterone, 
prolactin, progesterone, dehydroepiandrosterone) 
reportedly impact the immune response and the se-
verity of disease in SLE ; this also explains the sex 
disparity in SLE. Other environmental factors, 
such as ultraviolet radiation, vitamin D, infection 
(e.g., Epstein-Barr virus), vaccination, heavy met-
als, solvents, and pesticides are considered as risk 
factors for SLE6,16).
2.2 Mechanisms of NPSLE
Recent reports have identified two major mech-
anisms for the development of NPSLE, i.e., vascular 
mechanisms and neuroinflammatory mechanisms 
(Figure 1)1,2,6). Among the vascular mechanisms, 
vasculopathy is implicated in CNS damage in pa-
tients with NPSLE ; autopsy studies have shown 
pathological findings of multi-focal microinfarcts, 
small-vessel noninflammatory vasculopathy and oc-
clusion, embolism, cortical atrophy, and microhem-
orrhages1,17,18). Anti-phospholipid antibodies (aPL) 
and deposition of immune complexes are likely to be 
associated with these conditions1,18-20). Injury to 
large and small blood vessels mediated by aPL initi-
ates vascular damage, finally resulting in focal, and 
in part, diffuse neuropsychiatric events (seizures, 
cognitive dysfunction, etc.). The second mecha-
nism involves autoimmune inflammation mediated 
by autoantibodies, resulting in increased permeabili-
ty of the BBB, intrathecal formation of immune com-
plexes, and production of inflammatory mediators 
(IFN-α, IL-6, IL-8, IP-10, MCP-1, etc.)20,21). Direct 
CNS tissue injury caused by excitatory amino acid 
toxicity, oxidative stress, plasminogen activator in-
Table 1. Neuropsychiatric syndromes according to 
the criteria proposed by the American College 
of Rheumatology (Reference 3)
Central NPSLE Peripheral NPSLE
Aseptic meningitis1 Guillain-Barre syndrome
Cerebrovascular disease1 Autonomic neuropathy
Demyelinating syndrome1 Mononeuropathy
Headache1 Myasthenia gravis
Movement disorder1 Cranial neuropathy
Myelopathy1 Plexopathy
Seizure disorders1 Polyneuropathy
Acute confusional state2
Anxiety disorder2
Cognitive dysfunction2
Mood disorder2
Psychosis2
1. Focal NPSLE, 2. Diffuse NPSLE 
NPSLE : neuropsychiatric systemic lupus erythema-
tosus
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hibitor 1 (PAI-1), and matrix metalloproteinase 9 
(MMP9) activity have also been suggested20,22,23). 
These processes can cause CNS damage by activa-
tion of microglial cells and induction of neuronal cell 
death by apoptosis1,6), leading to mainly diffuse 
NSPLE symptoms, such as acute confusional state 
and psychosis1,20). As previously described, BBB 
dysfunction plays an important role in the pathogen-
esis of NSPLE. Normally, the brain is immunologi-
cally privileged and is sheltered from foreign sub-
stances in the circulation. The BBB limits the 
entry of soluble molecules and cells into brain pa-
renchyma and regulates both uptake into and efflux 
out of the brain1,20,24). Although the precise mecha-
nism of BBB dysfunction is still unclear, permeabili-
ty of the BBB can be affected by both SLE factors 
(immune complex deposition, cytokine/chemokines) 
and non-SLE factors (smoking or hypertension) that 
induce endothelial dysfunction in brain vascula-
ture1,8,20,25). In this regard, autoantibodies reacting 
with neuronal cells or those that have been reported 
as specific for each NPSLE symptom (from the cir-
culation or intrathecal production) might be associ-
ated with BBB dysfunction. Here, we review the 
representative autoantibodies that are potentially as-
sociated with the pathogenesis of NPSLE.
3. Autoantibodies potentially associated 
with specific NPSLE symptoms
Table 2 shows the representative autoantibod-
ies that have been recently described as potentially 
associated with NPSLE pathogenesis. More than 
100 autoantibodies have been described in patients 
with SLE or NPSLE26) ; however, none of these 
have been definitively implicated in the complex 
process of NPSLE pathogenesis. Therefore, exten-
sive research is ongoing to establish distinct patho-
genic roles for each autoantibody.
3.1 Anti-phospholipid antibodies (aPL)
The aPL antibody family targets proteins asso-
ciated with anionic phospholipids in the plasma 
membrane that regulate the blood clotting cas-
cade ; subsequent activation of procoagulants pro-
motes thrombosis and cerebral infarction27). Anti-
cardiolipin (aCL), anti-β2GP1 antibodies, and lupus 
anticoagulant (LAC) are the most widely investigat-
ed autoantibodies targeting phospholipids.    These 
have been recognized as major risk factors for 
NPSLE and are believed to contribute to the devel-
opment of thrombosis and other NPSLE symptoms, 
such as seizures, stroke, chorea, movement disor-
Fig. 1. Pathogenic mechanisms of neuropsychiatric systemic lupus erythematosus (NPSLE)
  Abbreviations : UV, ultraviolet 
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ders, cognitive dysfunction, and myelopathy28-32). 
In vitro studies have demonstrated direct binding of 
aPL with CNS cells ; in addition, intrathecal passive 
transfer of IgG isolated from aPL-positive patients 
was shown to induce cognitive dysfunction in 
mice33). At least, exacerbation of procoagulant state 
by aPL is believed to be associated with focal 
NPSLE causing intravascular thrombosis and cere-
bral ischemia20).
3.2  Anti-ribosomal P protein antibodies (anti-ribo P)
Anti-ribo P are specific autoantibodies occur-
ring in up to 46% of patients ; target epitopes are 
located in the C-terminal end of three highly con-
served phosphorylated proteins, P0, P1, and P2, 
which are present in the 60S subunit of ribo-
somes6,34). Many retrospective studies have sug-
gested an association between elevated serum or 
CSF levels of anti-ribo P and NPSLE manifesta-
tions ; however, the results have been contest-
ed35-37). Recent longitudinal studies and prospec-
tive studies have shown their association with lupus 
psychosis38-41). In a study by Hanly et al., anti-ribo 
P was found to be a predictor of psychosis42). In a 
mouse model, anti-ribo P recognized neurons in the 
hippocampus, cingulate, and primary olfactory piri-
form cortex, and induced long-term depressive-like 
behavior when introduced into cerebral ventri-
cles43). Matus et al. reported that anti-ribo P from 
psychiatric lupus induced a rapid and sustained in-
crease in calcium reflux and apoptosis in rat neurons 
expressing cell-surface P-antigen protein P331. 
The death of these neurons in specific brain regions 
(such as hippocampus) was found to affect the mem-
ory and emotional behavior of rats44). Direct evi-
dence of a pathogenic role for these antibodies in 
humans is still lacking ; nevertheless, experimental 
data and prospective studies support the role of anti-
ribo P in the causation of diffuse NPSLE.
3.3  Anti-N-methyl-D-aspartate receptor antibodies 
(anti-NMDA) 
Anti-NMDA antibodies occur in 30%-40% of 
patients with SLE ; these have been demonstrated 
as a subset of double-stranded DNA (dsDNA) anti-
bodies that cross-react with NMDA receptors, spe-
cifically with the NMDA receptor subunit 2 (NR2)45). 
NMDA receptors are widely distributed in the brain 
and localized within glutamatergic synapses ; a par-
ticularly high density is observed in the amygdala 
and hippocampus, which modulate cognitive func-
tion, emotional processes, and memory46,47). Acti-
vation of NMDA receptors is critical in learning and 
memory ; however, prolonged stimulation can cause 
apoptotic death of neuronal cells. The potential 
pathogenic role of anti-NMDA detected in CSF has 
been demonstrated in both in vitro and in vivo stud-
ies48,49). Interestingly, no neuronal damage was ob-
served if the BBB remained intact ; however, sever-
al pathological changes were detected when the 
Table 2. Representative autoantibodies associated with NPSLE 
Target of autoantibodies
(autoantibodies)
Serum/CSF Prevalence in 
SLE patients
Associated NPSLE symptoms
Phospholipid :
β2-glycoprotein 1 and cardiolipin 
(aCL-Ab)
Serum, CSF Up to 45% Focal NPSLE (CVD, seizures, chorea)
Diffuse NPSLE (cognitive dysfunction, psychosis, 
depression, headache)
Ribosomal P protein Serum, CSF 6%-46% Elevated titers in active SLE
(anti-ribosmal P Ab) Diffuse NPSLE (psychosis, depression)
NMDA receptor subtype 2
(anti-NMDA/NR2 Ab)
Serum, CSF 30%-40% Diffuse NPSLE (depression cognitive dysfunction)
MAP-2 (anti-MAP-2 Ab) Serum, CSF 17%, 33.3% (CSF) Focal NPSLE (seizures, chorea, sensory neuropathy)
Diffuse NPSLE (psychosis, headache)
U1 ribonucleoprotein
(Anti-U1RNP Ab)
Structural endothelial proteins
(AECA)
Serum, CSF
Serum
18% (CSF)
17-75%
NPSLE in general
Psychosis, depression
TPI (anti-TPI Ab) Serum, CSF 30%-40% Focal NPSLE (aseptic meningitis)
Less frequent in acute confusional state
GAPDH (anti-GAPDH Ab) Serum 47% Increased intracranial pressure, cognitive dysfunc-
tion
AECA : anti-endothelial cell antibody ; aCL : anti-cardiolipin ; CVD : cerebrovascular disease ; CSF : cerebrospinal 
fluid ; GAPDH : glyceraldehyde-3-phosphate dehydrogenase ; MAP-2 : microtubule-associated protein 2 ; NMDA/
NR2 : N-methyl-D-aspartate receptor 2 ; NPSLE : neuropsychiatric systemic lupus erythematosus ; U1-RNP : U1 ri
bonucleoprotein ; TPI : triosephosphate isomerase
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BBB was disrupted46-48). Correlation between CSF 
anti-NMDA and diffuse NPSLE manifestations has 
also been reported50). Furthermore, it has been 
suggested that anti-NR2/dsDNA antibodies may also 
help distinguish SLE patients with central diffuse 
NPSLE manifestations from patients with peripheral 
manifestations ; the pathogenic factors and mecha-
nisms underlying these manifestations are probably 
different51). Then, how do these autoantibodies 
gain access to the brain in SLE? Yoshio et al. have 
reported that anti-NR2/dsDNA antibodies from SLE 
patients activate endothelial cells and induce expres-
sion of surface molecules [intracellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion 
molecule 1 (VCAM-1)] as well as the production of 
IL-6 and IL-852). Hirohata et al. also reported that 
the severity of BBB damage plays a critical role in 
the development of diffuse NPSLE (acute confusion-
al state) through the accelerated entry of larger 
amounts of anti-NR2 antibodies into the CNS53). 
These results indicate that activation of BBB endo-
thelial cells by anti-NMDA may cause inflammation, 
disrupt the BBB, and promote entry of autoantibod-
ies into the CSF in patients with SLE.
3.4  Anti-microtubule-associated protein 2 antibodies 
(anti-MAP-2)
MAP-2 is one of the abundant groups of cyto-
skeletal components predominantly expressed in 
neurons54). MAP-2 regulates the nucleation and 
stabilization of microtubules, organelle transport 
protein kinases that are involved in signal transduc-
tion55). In a study by Yamada et al., 33.3% of NPSLE 
patients tested positive for anti-MAP-2 in the 
CSF54). Williams also reported that 17% of SLE pa-
tients had anti-MAP-2 in contrast to 4% of neuro-
logic injury/disease control patients56). Patients 
who tested positive for anti-MAP-2 exhibited neu-
ropsychiatric symptoms (psychosis, seizures, neu-
ropathy, and cerebritis). Moreover, both anti-ribo P 
titers and IL-6 levels in CSF were significantly 
higher in NPSLE patients having anti-MAP-2, indi-
cating some association between them54). 
3.5  Anti-U1 ribonucleoprotein antibodies (anti-
U1RNP)
Anti-U1RNP reacts with proteins that are asso-
ciated with U1 RNA and form U1 small nuclear ribo-
nucleoprotein (snRNP) ; these are detectable in 
25%-47% of SLE patients57). The snRNP are RNA-
protein complexes that are abundant in the 
nucleus ; these are involved in the nuclear process-
ing of pre-mRNA along with other proteins compris-
ing the spliceosome58). In a study by Sato et al., an-
ti-U1RNP in CSF, but not that in serum, was 
associated with NPSLE and mixed connective tissue 
disease59). Recent studies have shown that anti-
RNP as well as anti-Sm antibodies were less likely 
to be produced within the CNS ; this was assessed 
by calculating anti-RNP and anti-Sm indices in the 
CSF (indices of each reflect the intrathecal produc-
tion of these antibodies)60). Nevertheless, the de-
tailed role of anti-U1RNP should be further investi-
gated.
3.6 Anti-endothelial cell antibodies (AECA)
AECAs target a heterogenous group of antigens 
including structural endothelial proteins (ranging 
from 10 to 200 kDa) as well as adhesion molecules 
to endothelial cells ; these are found in a variety of 
diseases that are characterized by vessel wall dam-
age61). The reported prevalence of AECA in SLE 
patients ranges from 17% to 75%. Conti et al. 
found an association of serum AECA with psychosis 
and depression in NPSLE62). AECA can activate 
endothelial cells by inducing the expression of adhe-
sion molecules (ICAM-1 and VCAM-1) and stimu-
lating the production of cytokines (IL-1, IL-8) and 
chemokines [such as monocyte-chemotactic protein 
1 (MCP-1)]. AECA can also enhance the produc-
tion of tissue factor and von Willebrand factor, pro-
moting thrombosis. However, low specificity due 
to the lack of a standardized detection method and 
possible presence of natural AECAs (seen in a small 
percentage of healthy individuals and showing low 
affinity for their target antigens) limit the use of AE-
CAs as diagnostic and prognostic markers61,62).
3.7  Anti-triosephosphate isomerase antibodies (anti-
TPI)
Triosephosphate isomerase (TPI) is an impor-
tant glycolytic enzyme that catalyzes the intercon-
version of dihydroxyacetone phosphate and D-glyc-
eraldehyde-3-phosphate63). TPI is mediated solely 
by glycolysis in red blood cells and in brain cells, and 
its deficiency is associated with hemolytic anemia 
and neurological disorders. TPI is involved in the 
stability of neuronal microtubules63-66). Watanabe et 
al. have suggested some association with the patho-
genesis of NPSLE64-66). Furthermore, in our previ-
ous study, anti-TPI-TPI immune complex was de-
tected in the CSF of anti-TPI-positive NPSLE 
patients65). In a lupus model mouse, anti-TPI was 
detected in MRL/lpr mice ; in addition, anti-TPI 
was shown to bind to brain tissue in the meninges, 
choroid plexus, hippocampus, and periventricular le-
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sions using anti-TPI-producing hybridoma inocula-
tion into the brain hemisphere66). Recently, we re-
ported a higher frequency of aseptic meningitis in 
anti-TPI-positive NPSLE patients ; in addition, se-
rum anti-TPI index showed a positive correlation 
with serum IgG levels8). These results indicate 
that anti-TPI may be associated with NPSLE, main-
ly focal NPSLE (aseptic meningitis) ; the underlying 
mechanism may involve disruption of the BBB via 
formation of immune complexes in the CNS. In-
deed, the underlying mechanism of aseptic meningi-
tis in SLE patients is still unclear. A possible 
mechanism can be considered along with meningeal 
inflammation similar to that proposed for multiple 
sclerosis67) : immune cells first pass through the 
meninges via the bloodstream to the choroid plexus, 
as a part of immune surveillance. The interaction 
of autoimmune myelin-specific T cells with myelin-
loaded antigen-presenting cells can induce T cell re-
activation and production of inflammatory cytokines/
chemokines in the meninges. The additional in-
flammatory cells compromise local BBB integrity, 
which finally triggers immune cell infiltration into 
the CNS8,67). In any case, further investigation is 
needed to clarify the pathogenic role of anti-TPI in 
NPSLE.
3.8  Anti-glyceraldehyde-3-phosphate dehydrogenase 
antibodies (anti-GAPDH)
GAPDH is a glycolytic enzyme ; however, 
more recent evidence indicates that mammalian 
GAPDH performs a number of other functions68). 
Its activity contributes to membrane fusion, micro-
tubule bundling, phosphotransferase activity, nuclear 
RNA export, DNA replication and repair, and further, 
to neuronal cell death68,69). Takasaki et al. first re-
ported that anti-GAPDH is one of the elements of 
proliferating cell nuclear antigens, specifically those 
reactive with serum from SLE patients69). Further-
more, Delunardo et al. demonstrated the reaction of 
anti-GAPDH with neuronal cells and its association 
with cognitive dysfunction in patients with SLE70). 
Recently, Sun et al. also reported a positive correla-
tion of serum anti-GAPDH with SLEDAI-2K, ESR, 
IgG, and IgM ; in addition, anti-GAPDH showed an 
association with increased intracranial pressure, in-
dicating its potential role in the induction of brain 
tissue damage71). Although the direct effect of anti-
GAPDH is yet to be elucidated, it may serve as a 
useful biomarker for cerebrovascular damage in 
NPSLE patients. 
4. Conclusion 
Neuropsychiatric sequelae are among the main 
causes of morbidity and mortality in patients with 
SLE, but they are the least well-understood aspect 
of the disease. Appropriate evaluation and accurate 
classification of NP manifestations is an important 
focus of NPSLE treatment and research. However, 
its complex pathogenesis and polymorphic pheno-
type hampers the identification of pertinent, robust 
biomarkers. Further investigation of biomarkers 
(such as disease-specific or symptom-specific auto-
antibodies and cytokine/chemokine expression pro-
files) is required to increase our knowledge and im-
prove the management of NPSLE.
Conflict of interest 
The authors declare there is no conflict of inter-
est.
References 
 1. Jeltsch-David H, Muller S. Neuropsychiatric sys-
temic lupus erythematosus : pathogenesis and 
biomarkers. Nat Rev Neurol, 10 : 579-596, 
2014. doi : 10.1038/nrneurol.2014.148.
 2. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-
Beekman GM. Management of Neuropsychiatric 
Systemic Lupus Erythematosus : Current Ap-
proaches and Future Perspectives. Drugs, 
76 : 459-483, 2016. doi : 10.1007/s40265-015-
0534-3.
 3. [No authors listed]. The American College of 
Rheumatology nomenclature and case definitions 
for neuropsychiatric lupus syndromes. Arthritis 
Rheum, 42 : 599-608, 1999. 
 4. Hanly JG, Urowitz MB, Sanchez-Guerrero J, et 
al. Neuropsychiatric events at the time of diagno-
sis of systemic lupus erythematosus : an interna-
tional inception cohort study. Arthritis Rheum, 
56 : 265-273, 2007.
 5. Bertsias GK, Boumpas DT. Pathogenesis, diag-
nosis and management of neuropsychiatric SLE 
manifestations. Nat Rev Rheumatol, 6 : 358-367, 
2010. doi : 10.1038/nrrheum.2010.62.
 6. Govoni M, Bortoluzzi A, Padovan M, et al. The di-
agnosis and clinical management of the neuropsy-
chiatric manifestations of lupus. J Autoimmun, 
74 : 41-72, 2016. doi : 10.1016/j.jaut.2016.06.013.
 7. Kampylafka EI, Alexopoulos H, Kosmidis ML, et 
al. Incidence and prevalence of major central ner-
vous system involvement in systemic lupus 
erythematosus : a 3-year prospective study of 370 
7Symptom-specific autoantibodies in NPSLE
p a t i e n t s .  P L o S  O n e ,  8 : e 5 5 8 4 3 ,  2 0 1 3 . 
doi : 10.1371/journal.pone.0055843.
 8. Sato S, Yashiro M, Asano T, Kobayashi H, Wata-
nabe H, Migita K. Association of anti-triosephos-
phate isomerase antibodies with aseptic meningitis 
in patients with neuropsychiatric systemic lupus 
erythematosus. Clin Rheumatol, 36 : 1655-1659, 
2017. doi : 10.1007/s10067-017-3653-2.
 9. McGlasson S, Wiseman S, Wardlaw J, Dhaun N, 
Hunt DPJ. Neurological Disease in Lupus : To-
ward a Personalized Medicine Approach. Front 
Immunol, 9 : 1146, 2018. doi : 10.3389/fimmu. 
2018.01146. eCollection 2018.
10. Namjou B, Kothari PH, Kelly JA, et al. Evaluation 
of the TREX1 gene in a large multi-ancestral lupus 
cohort. Genes Immun, 12 : 270-279, 2011. 
doi : 10.1038/gene.2010.73.
11. Ellyard JI, Jerjen R, Martin JL, et al. Identification 
of a pathogenic variant in TREX1 in early-onset 
cerebral systemic lupus erythematosus by Whole-
exome sequencing. Arthritis Rheumatol, 66 : 
3382-3386, 2014.
12. Stetson DB, Ko JS, Heidmann T, Medzhitov 
R. Trex1 prevents cell-intrinsic initiation of auto-
i m m u n i t y.  C e l l ,  1 3 4 : 5 8 7 - 5 9 8 ,  2 0 0 8 . 
doi : 10.1016/j.cell.2008.06.032. 
13. Lundström E, Gustafsson JT, Jönsen A, et al. 
HLA-DRB1*04/*13 alleles are associated with 
vascular disease and antiphospholipid antibodies in 
systemic lupus erythematosus. Ann Rheum Dis, 
72 : 1018-1025, 2013. doi : 10.1136/annrheum-
dis-2012-201760.
14. Svenungsson E, Gustafsson J, Leonard D, et al. A 
STAT4 risk allele is associated with ischaemic 
cerebrovascular events and anti-phospholipid anti-
bodies in systemic lupus erythematosus. Ann 
Rheum Dis, 69 : 834-840, 2010. doi : 10.1136/
ard.2009.115535.
15. Rullo OJ, Tsao BP. Recent insights into the ge-
netic basis of systemic lupus erythematosus. Ann 
R h e u m  D i s ,  72  S u p p l  2 : i i 5 6 - 6 1 ,  2 0 1 3 . 
doi : 10.1136/annrheumdis-2012-202351.
16. Barbhaiya M, Costenbader KH. Environmental 
exposures and the development of systemic lupus 
erythematosus. Curr Opin Rheumatol, 28 : 497-
505, 2016. doi : 10.1097/BOR.0000000000000318.
17. Rhiannon JJ. Systemic lupus erythematosus in-
volving the nervous system : presentation, patho-
genesis, and management. Clin Rev Allergy Im-
munol, 34 : 356-360, 2008. doi : 10.1007/
s12016-007-8052-z.
18. Hanly JG, Walsh NM, Sangalang V. Brain patholo-
gy in systemic lupus erythematosus. J Rheuma-
tol, 19 : 732-741, 1992.
19. Mehta N, Uchino K, Fakhran S, et al. Platelet 
C4d is associated with acute ischemic stroke and 
stroke severity. Stroke, 39 : 3236-3241, 2008. 
doi : 10.1161/STROKEAHA.108.514687.
20. Hanly JG. Diagnosis and management of neuro-
psychiatric SLE. Nat Rev Rheumatol, 10 : 338-
347, 2014. doi : 10.1038/nrrheum.2014.15.
21. Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata 
S, Minota S. IL-6, IL-8, IP-10, MCP-1 and G-
CSF are significantly increased in cerebrospinal 
fluid but not in sera of patients with central neuro-
psychiatric lupus erythematosus.  Lupus, 
25 : 997-1003, 2016. doi : 10.1177/09612033166
29556.
22. Ainiala H, Hietaharju A, Dastidar P, et al. In-
creased serum matrix metalloproteinase 9 levels in 
systemic lupus erythematosus patients with neu-
ropsychiatric manifestations and brain magnetic 
resonance imaging abnormalities. Arthritis 
Rheum, 50 : 858-865, 2004.
23.	 Kwiecin´ski	 J,	Kłak	M,	Trysberg	E,	Blennow	K,	
Tarkowski A, Jin T. Relationship between elevat-
ed cerebrospinal fluid levels of plasminogen activa-
tor inhibitor 1 and neuronal destruction in patients 
with neuropsychiatric systemic lupus erythemato-
sus. Arthritis Rheum, 60 : 2094-2101, 2009. 
doi : 10.1002/art.24603.
24. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, 
Begley DJ. Structure and function of the blood-
brain barrier. Neurobiol Dis, 37 : 13-25, 2010. 
doi : 10.1016/j.nbd.2009.07.030.
25. Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi 
A. Mechanisms of neuropsychiatric lupus : The 
relative roles of the blood-cerebrospinal fluid barrier 
versus blood-brain barrier. J Autoimmun, 91 : 34-
44, 2018. doi : 10.1016/j.jaut.2018.03.001.
26. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld 
Y. Autoantibody explosion in systemic lupus 
erythematosus : more than 100 different antibod-
ies found in SLE patients. Semin Arthritis 
Rheum, 34 : 501-537, 2004.
27. Harris EN, Pierangeli S. Antiphospholipid anti-
bodies and cerebral lupus. Ann N Y Acad Sci, 
823 : 270-278, 1997.
28. Sanna G, Bertolaccini ML, Cuadrado MJ. Neuro-
psychiatric manifestations in systemic lupus 
erythematosus : prevalence and association with 
antiphospholipid antibodies. J Rheumatol, 
30 : 985-992, 2003.
29. Hanly JG. Attribution in the assessment of ner-
vous system disease in SLE. Rheumatology (Ox-
ford), 54 : 755-756, 2015. doi : 10.1093/rheuma-
tology/keu458.
30. Andrade RM, Alarcón GS, González LA, et al. Sei-
zures in patients with systemic lupus erythemato-
sus : data from LUMINA, a multiethnic cohort 
(LUMINA LIV). Ann Rheum Dis, 67 : 829-834, 
2008.
8 S. Sato et al.
31. Mok MY, Chan EY, Fong DY, Leung KF, Wong WS, 
Lau CS. Antiphospholipid antibody profiles and 
their clinical associations in Chinese patients with 
systemic lupus erythematosus. J Rheumatol, 
32 : 622-628, 2005.
32. McLaurin EY, Holliday SL, Williams P, Brey 
RL. Predictors of cognitive dysfunction in pa-
tients with systemic lupus erythematosus. Neu-
rology, 64 : 297-303, 2005.
33. Katzav A, Ben-Ziv T, Blank M, Pick CG, Shoenfeld Y, 
Chapman J. Antibody-specific behavioral effects : in-
tracerebroventricular injection of antiphospholipid anti-
bodies induces hyperactive behavior while anti-ribo-
somal-P antibodies induces depression and smell 
deficits in mice. J Neuroimmunol, 272 : 10-15, 
2014. doi : 10.1016/j.jneuroim.2014.04.003.
34. Mahler M, Kessenbrock K, Raats J, Williams R, 
Fritzler MJ, Blüthner M. Characterization of the 
human autoimmune response to the major C-ter-
minal epitope of the ribosomal P proteins. J Mol 
Med (Berl), 81 : 194-204, 2003.
35. Nojima Y, Minota S, Yamada A, Takaku F, Aotsuka S, 
Yokohari R. Correlation of antibodies to ribosom-
al P protein with psychosis in patients with sys-
temic lupus erythematosus. Ann Rheum Dis, 
51 : 1053-1055, 1992.
36. Haddouk S, Marzouk S, Jallouli M, et al. Clinical 
and diagnostic value of ribosomal P autoantibodies 
in systemic lupus erythematosus. Rheumatology 
(Oxford), 48 : 953-957, 2009. doi : 10.1093/
rheumatology/kep142.
37. Karassa FB, Afeltra A, Ambrozic A, et al. Accura-
cy of anti-ribosomal P protein antibody testing for 
the diagnosis of neuropsychiatric systemic lupus 
erythematosus : an international meta-analy-
sis. Arthritis Rheum, 54 : 312-324, 2006.
38. Bonfa E, Golombek SJ, Kaufman LD, et al. Asso-
ciation between lupus psychosis and anti-ribosomal 
P protein antibodies. N Engl J Med, 317 : 265-
271, 1987.
39. West SG, Emlen W, Wener MH, Kotzin BL. Neu-
ropsychiatric lupus erythematosus : a 10-year 
prospective study on the value of diagnostic 
tests. Am J Med, 99 : 153-163, 1995.
40. Watanabe T, Sato T, Uchiumi T, Arakawa M. Neu-
ropsychiatric manifestations in patients with sys-
temic lupus erythematosus : diagnostic and pre-
dictive value of longitudinal examination of anti-
ribosomal P antibody. Lupus, 5 : 178-183, 1996.
41. Briani C, Lucchetta M, Ghirardello A, et al. Neurolu-
pus is associated with anti-ribosomal P protein 
antibodies : an inception cohort study. J Autoimmun, 
32 : 79-84, 2009. doi : 10.1016/j.jaut.2008.12.002.
42. Hanly JG, Urowitz MB, Siannis F, et al. Autoanti-
bodies and neuropsychiatric events at the time of 
systemic lupus erythematosus diagnosis : results 
from an international inception cohort study. Ar-
thritis Rheum, 58 : 843-853, 2008.   doi : 10.1002/
art.23218.
43. Katzav A, Solodeev I, Brodsky O, et al. Induction 
of autoimmune depression in mice by anti-ribo-
somal P antibodies via the limbic system. Arthri-
tis Rheum, 56 : 938-948, 2007.
44. Matus S, Burgos PV, Bravo-Zehnder M, et al. An-
tiribosomal-P autoantibodies from psychiatric lu-
pus target a novel neuronal surface protein causing 
calcium influx and apoptosis. J Exp Med, 204 : 
3221-3234, 2007.
45. Lauvsnes MB, Omdal R. Systemic lupus erythe-
matosus, the brain, and anti-NR2 antibodies. J 
Neurol, 259 : 622-629, 2012. doi : 10.1007/
s00415-011-6232-5. 
46. Kowal C, DeGiorgio LA, Nakaoka T, et al. Cogni-
tion and immunity ; antibody impairs memo-
ry. Immunity, 21 : 179-188, 2004.
47. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Dia-
mond B. Immunity and behavior : antibodies al-
ter emotion. Proc Natl Acad Sci U S A, 103 : 
678-683, 2006.
48. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin 
JA, Volpe BT, Diamond B. A subset of lupus anti-
DNA antibodies cross-reacts with the NR2 gluta-
mate receptor in systemic lupus erythemato-
sus. Nat Med, 7 : 1189-1193, 2001.
49. Husebye ES, Sthoeger ZM, Dayan M, et al. Auto-
antibodies to a NR2A peptide of the glutamate/
NMDA receptor in sera of patients with systemic 
lupus erythematosus. Ann Rheum Dis, 64 : 
1210-1213, 2005.
50. Arinuma Y, Yanagida T, Hirohata S. Association of 
cerebrospinal fluid anti-NR2 glutamate receptor 
antibodies with diffuse neuropsychiatric systemic 
lupus erythematosus. Arthritis Rheum, 58 : 
1130-1115, 2008. doi : 10.1002/art.23399.
51. Fragoso-Loyo H, Cabiedes J, Orozco-Narváez A, et 
al. Serum and cerebrospinal fluid autoantibodies 
in patients with neuropsychiatric lupus erythema-
tosus. Implications for diagnosis and pathogene-
sis. PLoS One, 3 : e3347, 2008. doi : 10.1371/
journal.pone.0003347.
52. Yoshio T, Okamoto H, Hirohata S, Minota S. IgG 
anti-NR2 glutamate receptor autoantibodies from 
patients with systemic lupus erythematosus acti-
vate endothelial cells. Arthritis Rheum, 65 : 
457-463, 2013. doi : 10.1002/art.37745.
53. Hirohata S, Arinuma Y, Yanagida T, Yoshio T. 
Blood-brain barrier damages and intrathecal syn-
thesis of anti-N-methyl-D-aspartate receptor NR2 
antibodies in diffuse psychiatric/neuropsychological 
syndromes in systemic lupus erythematosus. Ar-
thritis Res Ther, 16 : R77, 2014.    doi : 10.1186/
ar4518.
9Symptom-specific autoantibodies in NPSLE
54. Yamada Y, Nozawa K, Nakano S, et al. Antibodies 
to microtubule-associated protein-2 in the cerebro-
spinal fluid are a useful diagnostic biomarker for 
neuropsychiatric systemic lupus erythemato-
sus. Mod Rheumatol, 26 : 562-568, 2016. doi : 
10.3109/14397595.2015.1123345.
55. Sánchez C, Díaz-Nido J, Avila J. Phosphorylation 
of microtubule-associated protein 2 (MAP2) and its 
relevance for the regulation of the neuronal cyto-
skeleton function. Prog Neurobiol, 61 : 133-168, 
2000. 
56. Williams RC Jr, Sugiura K, Tan EM. Antibodies to 
microtubule-associated protein 2 in patients with 
neuropsychiatric systemic lupus erythemato-
sus. Arthritis Rheum, 50 : 1239-1247, 2004.
57. Migliorini P, Pratesi F, Tommasi C, Anzilotti 
C. The immune response to citrullinated anti-
gens in autoimmune diseases. Autoimmun Rev, 
4 : 561-564, 2005.
58. Dema  B ,  Cha r le s  N .  Aut oa n t i bod ies  i n 
SLE : Specificities, Isotypes and Receptors. Anti-
bodies (Basel), 5. pii : E2, 2016.    doi : 10.3390/
antib5010002.
59. Sato T, Fujii T, Yokoyama T, et al. Anti-U1 RNP 
antibodies in cerebrospinal fluid are associated with 
central neuropsychiatric manifestations in systemic 
lupus erythematosus and mixed connective tissue 
disease. Arthritis Rheum, 62 : 3730-3740, 2010. 
doi : 10.1002/art.27700.
60. Hirohata S, Sakuma Y, Yanagida T, Yoshio T. As-
sociation of cerebrospinal fluid anti-Sm antibodies 
with acute confusional state in systemic lupus ery-
thematosus. Arthritis Res Ther, 16 : 450, 2014. 
doi : 10.1186/s13075-014-0450-z.
61. Perricone C, Pendolino M, Olivieri M, Conti F, 
Valesini G, Alessandri C. Neuropsychiatric mani-
festations associated with anti-endothelial cell an-
tibodies in systemic lupus erythematosus. Isr 
Med Assoc J, 17 : 171-178, 2015.
62. Conti F, Alessandri C, Bompane D, et al. Autoan-
tibody profile in systemic lupus erythematosus 
with psychiatric manifestations : a role for anti-en-
dothelial-cell antibodies. Arthritis Res Ther, 
6 : R366-372, 2004.
63. Orosz F, Wágner G, Liliom K, et al. Enhanced as-
sociation of mutant triosephosphate isomerase to 
red cel l  membranes and to brain microtu-
bules. Proc Natl Acad Sci U S A, 97 : 1026-1031, 
2000. 
64. Watanabe H, Seino T, Sato Y. Antibodies to trios-
ephosphate isomerase in patients with neuropsy-
chiatric lupus. Biochem Biophys Res Commun, 
321 : 949-953, 2004.
65. Sasajima T, Watanabe H, Sato S, Sato Y, Ohira 
H. Anti-triosephosphate isomerase antibodies in 
cerebrospinal fluid are associated with neuropsy-
chiatric lupus. J Neuroimmunol, 181 : 150-156, 
2006.
66. Sato S, Watanabe H, Shio K, Kobayashi H, Ohira 
H. Association of anti-triosephosphate isomerase 
antibody and MRL/MpJ-Faslpr mouse. J Neuro-
immunol, 226 : 110-115, 2010. doi : 10.1016/
j.jneuroim.2010.05.041.
67. Russi AE, Brown MA. The meninges : new ther-
apeutic targets for multiple sclerosis. Transl Res, 
165 : 255-269, 2015. doi : 10.1016/j.trsl.2014.08.005
68. Sirover MA. Role of the glycolytic protein, glyc-
eraldehyde-3-phosphate dehydrogenase, in normal 
cell function and in cell pathology. J Cell Bio-
chem, 66 : 133-140, 1997.
69. Takasaki Y, Kaneda K, Matsushita M, et al. Glyc-
eraldehyde 3-phosphate dehydrogenase is a novel 
autoantigen leading autoimmune responses to pro-
liferating cell nuclear antigen multiprotein com-
plexes in lupus patients. Int Immunol, 16 : 1295-
1304, 2004.
70. Delunardo F, Soldati D, Bellisario V, et al. Anti-
GAPDH Autoantibodies as a Pathogenic Determi-
nant and Potential Biomarker of Neuropsychiatric 
Diseases. Arthritis Rheumatol, 68 : 2708-2716, 
2016. doi : 10.1002/art.39750.
71. Sun J, Li X, Zhou H, et al. Anti-GAPDH Autoanti-
body Is Associated with Increased Disease Activity 
and Intracranial Pressure in Systemic Lupus Ery-
thematosus. J Immunol Res, 2019 : 7430780, 
2019. doi : 10.1155/2019/7430780. eCollection 
2019.
